Drug intelligence / Profile preview

BJTJ-0066

Development stage: Preclinical
Lead developer: Simcere Pharmaceutical Group

Overview

BJTJ-0066 is an investigational drug candidate currently in the preclinical stage of development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), formerly known as non-alcoholic steatohepatitis (NASH). Developed by Beijing Tuobixi Pharmaceutical (also known as Beijing Tuojie Pharmaceutical), the drug is part of a pipeline focused on chronic metabolic and cardiovascular diseases. While specific details regarding its molecular target and modality have not been publicly disclosed, the company's technology platforms specialize in innovative biological drugs, including fatty acid-modified peptides, recombinant proteins, and monoclonal antibodies. BJTJ-0066 is currently undergoing preclinical evaluation to assess its efficacy in addressing the inflammatory and fibrotic components of MASH.

Beyond the preview

Go deeper on BJTJ-0066.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BJTJ-0066.

Explore the full profile